title: Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial.
abstract: OBJECTIVE
  Fungal septicemia is a devastating disease in the neonate, especially in the low birth weight preterm infant who is especially vulnerable to disseminated fungal sepsis. The objective of this study was to compare the efficacy, safety and overall convenience of fluconazole vs. amphotericin B for the treatment of disseminated fungal sepsis in neonates.
  
  
  METHODS
  A prospective, randomized, collaborative study conducted at two South African neonatal units.
  
  
  METHODS
  Twenty-four infants with proven fungal septicemia were treated from June, 1992, to June, 1993. Twelve received fluconazole, 11 received amphotericin B and 1 was excluded. Assessment of hepatic, renal and hematologic functions were performed before, during and after treatment. The two groups were comparable at the time of enrollment into the study.
  
  
  RESULTS
  Infants receiving amphotericin B had significantly higher values of total and direct bilirubin and alkaline phosphatase values at the end of treatment, while the fluconazole group showed a significant increase in the platelet count. The cumulative total numbers of days receiving intravenous therapy for the administration of antifungal drugs were 57 for the fluconazole group and 162 for the amphotericin group; no central lines were needed in the fluconazole group, whereas 3 babies given amphotericin B had central catheters for a cumulative total of 27 days. The case fatality rate was 33% in the fluconazole group and 45% in the amphotericin B group; there was still proof of fungal septicemia at the time of death in 1 patient given amphotericin B and 2 given fluconazole.
  
  
  CONCLUSIONS
  Fluconazole showed fewer side effects than amphotericin B and was more convenient to use.
authors.affiliation: Department of Pediatrics and Child Health, Ga-Rankuwa Hospital, Medical University of Southern Africa, South Africa.
authors.forename: M
authors.initials: M
authors.lastname: Driessen
authors.forename: J B
authors.initials: JB
authors.lastname: Ellis
authors.forename: P A
authors.initials: PA
authors.lastname: Cooper
authors.forename: S
authors.initials: S
authors.lastname: Wainer
authors.forename: F
authors.initials: F
authors.lastname: Muwazi
authors.forename: D
authors.initials: D
authors.lastname: Hahn
authors.forename: H
authors.initials: H
authors.lastname: Gous
authors.forename: F P
authors.initials: FP
authors.lastname: De Villiers
mesh_terms: D000284:Administration, Oral; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003906:Developing Countries; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007363:Intensive Care Units, Neonatal; D008297:Male; D011446:Prospective Studies; D013019:South Africa; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole